Bicycle Therapeutics (BCYC) Competitors $7.10 +0.01 (+0.14%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$7.16 +0.06 (+0.77%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCYC vs. ARQT, ADPT, CGON, ANIP, VCEL, BEAM, DYN, APGE, TWST, and TVTXShould you be buying Bicycle Therapeutics stock or one of its competitors? The main competitors of Bicycle Therapeutics include Arcutis Biotherapeutics (ARQT), Adaptive Biotechnologies (ADPT), CG Oncology (CGON), ANI Pharmaceuticals (ANIP), Vericel (VCEL), Beam Therapeutics (BEAM), Dyne Therapeutics (DYN), Apogee Therapeutics (APGE), Twist Bioscience (TWST), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry. Bicycle Therapeutics vs. Its Competitors Arcutis Biotherapeutics Adaptive Biotechnologies CG Oncology ANI Pharmaceuticals Vericel Beam Therapeutics Dyne Therapeutics Apogee Therapeutics Twist Bioscience Travere Therapeutics Arcutis Biotherapeutics (NASDAQ:ARQT) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends. Do analysts prefer ARQT or BCYC? Arcutis Biotherapeutics currently has a consensus target price of $19.80, suggesting a potential upside of 23.90%. Bicycle Therapeutics has a consensus target price of $22.22, suggesting a potential upside of 212.99%. Given Bicycle Therapeutics' higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Arcutis Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Bicycle Therapeutics 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.70 Which has preferable valuation and earnings, ARQT or BCYC? Arcutis Biotherapeutics has higher revenue and earnings than Bicycle Therapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcutis Biotherapeutics$196.54M9.75-$140.04M-$0.75-21.31Bicycle Therapeutics$35.28M13.94-$169.03M-$3.51-2.02 Do institutionals & insiders hold more shares of ARQT or BCYC? 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Comparatively, 8.5% of Bicycle Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to ARQT or BCYC? In the previous week, Arcutis Biotherapeutics had 8 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 10 mentions for Arcutis Biotherapeutics and 2 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 1.69 beat Arcutis Biotherapeutics' score of 1.13 indicating that Bicycle Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicycle Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is ARQT or BCYC more profitable? Arcutis Biotherapeutics has a net margin of -35.40% compared to Bicycle Therapeutics' net margin of -1,257.00%. Bicycle Therapeutics' return on equity of -32.43% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arcutis Biotherapeutics-35.40% -62.62% -25.16% Bicycle Therapeutics -1,257.00%-32.43%-26.80% Which has more risk & volatility, ARQT or BCYC? Arcutis Biotherapeutics has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. SummaryArcutis Biotherapeutics beats Bicycle Therapeutics on 9 of the 16 factors compared between the two stocks. Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCYC vs. The Competition Export to ExcelMetricBicycle TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$491.70M$3.12B$5.82B$9.76BDividend YieldN/A2.24%4.40%4.04%P/E Ratio-2.0221.1331.3826.05Price / Sales13.94396.87472.41122.40Price / CashN/A43.2325.7828.78Price / Book0.629.879.526.07Net Income-$169.03M-$54.06M$3.26B$265.39M7 Day Performance-4.57%2.62%2.14%2.00%1 Month Performance-17.44%3.25%3.22%0.46%1 Year Performance-68.28%10.82%30.19%18.88% Bicycle Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCYCBicycle Therapeutics3.3188 of 5 stars$7.10+0.1%$22.22+213.0%-68.3%$491.70M$35.28M-2.02240News CoveragePositive NewsShort Interest ↓ARQTArcutis Biotherapeutics1.7779 of 5 stars$16.74-0.9%$19.80+18.3%+62.6%$2.03B$196.54M-22.32150News CoveragePositive NewsADPTAdaptive Biotechnologies2.4123 of 5 stars$12.41-4.8%$12.38-0.3%+167.5%$1.99B$178.96M-15.13790News CoverageAnalyst RevisionCGONCG Oncology1.3614 of 5 stars$26.13+1.7%$55.30+111.6%-27.3%$1.96B$1.14M-14.7661ANIPANI Pharmaceuticals3.2576 of 5 stars$89.71+2.6%$84.75-5.5%+47.6%$1.90B$614.38M-116.50600News CoverageAnalyst UpgradeInsider TradeVCELVericel2.4551 of 5 stars$36.32+0.1%$60.33+66.1%-24.9%$1.83B$237.22M302.69300Positive NewsBEAMBeam Therapeutics2.2261 of 5 stars$17.10-4.0%$48.45+183.4%-37.9%$1.80B$63.52M-3.80510DYNDyne Therapeutics3.6298 of 5 stars$12.33-0.4%$33.80+174.1%-73.0%$1.76BN/A-3.19100Positive NewsAPGEApogee Therapeutics3.7747 of 5 stars$36.90-1.0%$99.00+168.3%-20.9%$1.72BN/A-8.9391Positive NewsTWSTTwist Bioscience4.1428 of 5 stars$28.02-0.4%$49.40+76.3%-34.5%$1.70B$312.97M-19.32990Positive NewsTVTXTravere Therapeutics2.3945 of 5 stars$18.77-0.3%$32.21+71.6%+99.6%$1.68B$233.18M-9.20460News CoveragePositive NewsAnalyst Downgrade Related Companies and Tools Related Companies Arcutis Biotherapeutics Competitors Adaptive Biotechnologies Competitors CG Oncology Competitors ANI Pharmaceuticals Competitors Vericel Competitors Beam Therapeutics Competitors Dyne Therapeutics Competitors Apogee Therapeutics Competitors Twist Bioscience Competitors Travere Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCYC) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access